Fab Inhibitors: Addressing Unmet Medical Needs Caused by Bacterial Resistance

Germinated from assets acquired in 2003 from GSK, Affinium’s antibacterial programs now
include a broad base of intellectual property: issued and pending composition of matter patents
on potent orally available small molecule inhibitors, genes, proteins, assays, crystal structures
and combinations of Fab inhibitors with known antibiotics. These assets represent a new class
of antibiotics with a unique mechanism of action, targeting an unexploited pathway, bacterial fatty
acid biosynthesis. With a lead compound entering the clinic, Fab inhibitors represent a significant
opportunity for multiple products and partnering opportunities.